Precigen (PGEN) Return on Capital Employed (2013 - 2026)
Precigen (PGEN) posted quarterly Return on Capital Employed of 74.55% for Q1 2026, up 4330.0% year-over-year from 1.68% in Q1 2025, and up 14.94% quarter-over-quarter from 87.65% in Q4 2025.
Precigen (PGEN) Return on Capital Employed (2013 - 2026) Analysis & Trends
Precigen (PGEN) has reported Return on Capital Employed for 14 consecutive years, with 74.55% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4330.0% year-over-year to 74.55%; the TTM figure through Mar 2026 stood at 74.55% (up 4330.0% YoY), while the FY2025 annual figure was 97.73%, up 890.0% from the prior year.
- Return on Capital Employed advanced to 74.55% in Q1 2026 per PGEN's latest filing, from 87.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.49% in Q1 2022 and bottomed at 246.47% in Q3 2024.
- Historically, Return on Capital Employed has averaged 88.61% across 5 years, with a median of 74.55% in 2026.
- Annual changes were most pronounced in 2024 — Return on Capital Employed slumped 19393 bps — and 2025, when it soared 13418 bps.
- Precigen's Return on Capital Employed stood at 47.64% in 2022, then sank by 42 bps to 67.46% in 2023, then plunged by 116 bps to 145.42% in 2024, then surged by 40 bps to 87.65% in 2025, then increased by 15 bps to 74.55% in 2026.
- Business Quant data shows PGEN's Return on Capital Employed at 74.55% in Q1 2026, 87.65% in Q4 2025, and 112.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | -31.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.57% |
| Mar 31, 2026 | -74.55% |
| Dec 31, 2025 | -87.65% |
| Sep 30, 2025 | -112.29% |
| Jun 30, 2025 | -113.01% |
| Mar 31, 2025 | -117.85% |
| Dec 31, 2024 | -145.42% |
| Sep 30, 2024 | -246.47% |
| Jun 30, 2024 | -173.39% |
| Mar 31, 2024 | -88.19% |
| Dec 31, 2023 | -67.46% |
| Sep 30, 2023 | -52.54% |
| Jun 30, 2023 | -38.20% |
| Mar 31, 2023 | -42.33% |
| Dec 31, 2022 | -47.64% |
| Sep 30, 2022 | -40.89% |
| Jun 30, 2022 | -30.06% |
| Mar 31, 2022 | -28.49% |
| Dec 31, 2021 | -26.16% |
| Sep 30, 2021 | -27.89% |